Design of Novel Enantiopure Dispirooxindolopyrrolidine-Piperidones as Promising Candidates toward COVID-19: Asymmetric Synthesis, Crystal Structure and In Silico Studies

Molecules. 2022 Jun 20;27(12):3945. doi: 10.3390/molecules27123945.

Abstract

Despite the effectiveness of COVID-19 vaccines, there is still an urgent need for discovering new anti-viral drugs to address the awful spread and transmission of the rapidly modifiable virus. In this study, the ability of a small library of enantiomerically pure spirooxindolopyrrolidine-grafted piperidones to inhibit the main protease of SARS-CoV-2 (Mpro) is evaluated. These spiroheterocycles were synthesized by 1,3-dipolar cycloaddition of various stabilized azomethine ylides with chiral dipolarophiles derived from N-[(S)-(-)-methylbenzyl]-4-piperidone. The absolute configuration of contiguous carbons was confirmed by a single crystal X-ray diffraction analysis. The binding of these compounds to SARS-CoV-2 Mpro was investigated using molecular docking and molecular dynamics simulation. Three compounds 4a, 4b and 4e exhibited stable binding modes interacting with the key subsites of the substrate-binding pocket of SARS-CoV-2 Mpro. The synthesized compounds represent potential leads for the development of novel inhibitors of SARS-CoV-2 main protease protein for COVID-19 treatment.

Keywords: Hirshfeld analysis; SARS-CoV-2; crystal structure; enantiopure spirooxindolopyrrolidine-piperidones; molecular docking; molecular dynamics.

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • COVID-19 Drug Treatment*
  • COVID-19 Vaccines
  • Cysteine Endopeptidases / chemistry
  • Humans
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Piperidones*
  • Protease Inhibitors / chemistry
  • SARS-CoV-2
  • Viral Nonstructural Proteins / metabolism

Substances

  • Antiviral Agents
  • COVID-19 Vaccines
  • Piperidones
  • Protease Inhibitors
  • Viral Nonstructural Proteins
  • Cysteine Endopeptidases

Grants and funding

This research received no external funding.